Themis Medicare Ltd (THEMISMED) — shareholding pattern, promoter holding, financials and share price
About Themis Medicare Ltd (THEMISMED)
Themis Medicare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as THEMISMED and on the BSE under scrip code 530199. Its ISIN is INE083B01024.
Incorporated in 1969, Themis Medicare manufactures Formulation and API pharmaceutical products [1]
Themis Medicare Limited manufactures finished pharmaceutical formulations and synthetic Active Pharmaceutical Ingredients (APIs), operates a hospital-focused commercial division, and exports to over 44 countries while operating three state-of-the-art manufacturing facilities across India with EU GMP certifications for key units.
Q3 FY26 showed a notable profitability turnaround with consolidated revenue of ₹90.13 crore, EBITDA of ₹9.8 crore (10.9% margin) and PAT of ₹10.09 crore, driven by API growth and cost rationalization, despite 9M FY26 revenue falling 20.4% year-on-year to ₹265.7 crore and negative cumulative profitability.
Listed peers in Pharmaceuticals: Accent Microcell Ltd, Fermenta Biotech Ltd, Bajaj Healthcare Ltd, Wanbury Ltd, Bharat Parenterals Ltd, Kopran Ltd.
Valuation & Returns
10 Jul 2026At ₹117.8 a share on 10 Jul 2026, Themis Medicare Ltd (THEMISMED) was valued at a price-to-earnings ratio of 951.7x against an industry P/E of 36.41x and a price-to-book of 2.69x on a book value of ₹43.71 per share as of Mar 2025. Solomo computes return on equity of 0.28% and return on capital employed of 2.6% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 951.7x
- Industry P/E
- 36.41x
- P/B
- 2.69x
- EPS (TTM)
- ₹0.12
- Book value / share
- ₹43.71
- ROE
- 0.28%
- ROCE
- 2.6%
- ROA
- 0.19%
- Debt / equity
- 0.21x
- Dividend yield
- 0.42%
- EBITDA margin
- 6.7%
- 52-week range
- ₹65 – ₹147.99
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Themis Medicare Ltd (THEMISMED) reported revenue of ₹342 crore, net profit of ₹1 crore and earnings per share of ₹0.12. That compares with revenue of ₹406 crore and net profit of ₹30 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹76.53 crore and net profit ₹8.89 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 395 | 354 | 382 | 406 | 342 |
| Net profit (₹ cr) | 73 | 57 | 44 | 30 | 1 |
| EPS (₹) | 7.92 | 6.18 | 4.73 | 3.24 | 0.12 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.79% | 15.00% | 0.91% | 6.22% |
| Profit growth | 5.27% | 8.50% | -27.03% | -31.46% |
| Stock price CAGR | 7% | 5% | -9% | -10% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 67.11% of Themis Medicare Ltd (THEMISMED) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.01% and domestic institutional investors (DII) hold 0.01%. Promoters have pledged 43.4% of their holding. Market capitalisation was ₹1,085 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Anuj Anantrai Sheth 3.8%, Zafar Ahmadullah 2.11%, HUF 1.75%, Za Capital Services India Private Ltd 1.53%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 67.11% | 43.4% | 0.01% | 0.01% | 32.89% |
| Mar 2026 | 67.11% | 2.4% | 0.11% | 0.01% | 32.89% |
| Dec 2025 | 67.11% | 2.4% | 0.05% | 0.01% | 32.89% |
| Sep 2025 | 67.15% | 2.4% | 0.06% | 0.01% | 32.85% |
| Jun 2025 | 67.15% | 2.4% | 0.1% | 0.01% | 32.85% |
| Mar 2025 | 67.15% | 2.4% | 0.14% | 0.01% | 32.85% |
| Dec 2024 | 67.15% | 2.4% | 0.1% | 0.01% | 32.85% |
| Sep 2024 | 67.15% | 2.4% | 0.1% | 0.01% | 32.85% |